Xcout Intel
Georgiamune, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Georgiamune, Inc. among biotechnology companies — ranked by similarity to what Georgiamune, Inc. actually does, not by market-cap band.
Subscribe to see Georgiamune, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Georgiamune, Inc.
Georgiamune Inc. is a clinical-stage science and discovery biotechnology company headquartered in Gaithersburg, Maryland, operating within the BioHealth Capital Region.
Georgiamune, Inc. at a glance
Georgiamune, Inc. is a biotechnology company headquartered in United States. It has raised at least $167.7M across the 2 funding rounds on record. Its most recent funding round raised $92.7M in July 2026. Xcout tracks 15 named people at Georgiamune, Inc., including Patrick Thompson (Chief Financial Officer).
Georgiamune, Inc. leadership
- Patrick ThompsonChief Financial Officer
- Jacques Banchereau, PhDChief Innovation Officer
- Ramy Ibrahim, MDChief Medical and Strategy Officer
- Samir N. KhleifFounder/President/Chief Executive Officer
- Amy AbernethyCofounder, Highlander Health
- Mikayel Mkrtichyan, PhDSenior Vice President
9 more named people on record for Georgiamune, Inc., with roles, board committees and tenure — see the full roster →
Georgiamune, Inc. funding rounds
At least $167.7M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $92.7M | — | |
| Series A | $75M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Georgiamune, Inc. competitors
Ranked by semantic similarity — how close each company is to Georgiamune, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Similar biotechnology company
Viela Bio, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to the discovery, development, and commercialization of novel therapies for autoimmune and severe inflammatory diseases.
Similar biotechnology company
miRecule, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, focused on developing RNA therapeutics.
Similar biotechnology company
GlobeImmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Louisville, Colorado, focused on developing therapeutic vaccines to treat cancer and infectious diseases.
Biotech
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Biotech
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Similar biotechnology company
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Similar biotechnology company
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Biotech
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Biotech
Deka Biosciences, Inc. is an early-stage biotechnology holding company located in Germantown, Maryland, focused on developing and delivering life-changing medicines for cancer patients.
Similar biotechnology company
Adaptive Phage Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that is advancing the APT phage bank. The company focuses on developing phage-based therapeutics to address bacterial infections.
Similar biotechnology company
Precision Biologics, Inc. is a biotechnology research company headquartered in Bethesda, Maryland, focused on developing monoclonal antibodies targeted against specific tumor antigens.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Georgiamune, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Georgiamune, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →